Feature | June 12, 2014

PET/MR Superior for Verifying Coronary Arterial Disease

Study finds the newest hybrid cardiac molecular imaging system highly effective for the detection

June 12, 2014 — Ischemic heart disease, a narrowing of the arteries supplying blood to the heart, is a leading cause of death throughout the world. A hybrid molecular imaging technique called positron emission tomography and magnetic resonance imaging (PET/MR), which tells doctors vital information about cardiac and arterial function, has been found to be an effective molecular imaging tool for detecting coronary artery disease (CAD), say researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI).

Often patients suspected of having CAD undergo a stress test called myocardial perfusion imaging (MPI) to smoke out areas of arterial ischemia and risk of myocardial infarction, or heart attack. Many undergo a molecular imaging scan called single photon emission computed tomography (SPECT), but in recent years PET/MR has emerged as a potential alternative due to its superiority for imaging the structures of soft tissues and the physiological function of the heart. This clinical study showed that PET/MR is consistently accurate using coronary angiography as the reference standard for detecting CAD.

“By combining two advanced imaging modalities, PET and MR, cardiac PET/MR imaging allows a union of anatomic information with MR and functional information with PET for a comprehensive view of the of the heart,” said principal author Jeffrey M.C. Lau, M.D., Ph.D., from Washington University in St. Louis, Mo. “This allows us to predict or rule out coronary artery disease with more certainty, and in some instances, it allows us to detect disease processes such as areas of hibernating heart muscle that would not have been detected using conventional stress testing methods like SPECT.”

In addition, cardiac perfusion PET/MR can be performed in a shorter timeframe than SPECT and is associated with a lower dose of radiation per procedure, and MR can be used to produce an almost of disease in the arteries of the heart when compared to industry standard cinematic, multiple-frame sequence of the motion in specific regions of the heart muscle, most notably the left ventricle, which pumps oxygenated blood back into the body through the aorta. PET also provides quantitative data about blood flow in addition to the visual interpretation of disease.

The study involved 10 patients with reversible ischemia as indicated by SPECT-MPI. Scientists administered a radionuclide PET imaging agent called N-13 ammonia plus an MR contrast agent called gadolinium and the pharmaceutical Regadenoson, which imitates the stress of exercise. The researchers optimized the cardiac PET/MR imaging protocol in order to register areas of reduced perfusion of blood using MR with PET data about myocardial blood flow. The results showed that PET/MR imaging was very accurate in diagnostic coronary artery diseases. In this small sample, PET/MR had 100 percent sensitivity, 80 percent specificity and 100 percent negative predictive value. Those numbers compare favorably to SPECT in this study group.

This study was conducted in conjunction with Siemens Medical Solutions and funded in part by Astellas Pharma Inc.

For more information: www.snmmi.org

Related Content

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI
Technology | Magnetic Resonance Imaging (MRI) | November 15, 2018
Canon Medical Systems USA Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on its new...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages